var data={"title":"Management of the infant whose mother has received group B streptococcal chemoprophylaxis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management of the infant whose mother has received group B streptococcal chemoprophylaxis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/contributors\" class=\"contributor contributor_credentials\">Karen M Puopolo, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/contributors\" class=\"contributor contributor_credentials\">Carol J Baker, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/contributors\" class=\"contributor contributor_credentials\">Leonard E Weisman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/contributors\" class=\"contributor contributor_credentials\">Carrie Armsby, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Group B streptococcus<em> </em>(GBS or <em>Streptococcus agalactiae</em>) is an encapsulated gram-positive bacterium that colonizes the human gastrointestinal and genital tracts. GBS is the most frequent bacterial pathogen in neonates, and maternal colonization is the single most important risk factor for early-onset (younger than seven days of age) GBS infection [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Screening pregnant women for GBS colonization and administering intrapartum antibiotic prophylaxis (IAP) against GBS is the recommended approach to the prevention of early-onset infection in neonates [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/4,5\" class=\"abstract_t\">4,5</a>]. However, this approach does not prevent all cases of early-onset GBS disease and does not prevent late-onset GBS disease. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention#H1765500823\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;, section on 'Missed cases'</a>.)</p><p>Rapid detection and early initiation of appropriate antimicrobial therapy is necessary to minimize morbidity and mortality among the cases that continue to occur.</p><p>The evaluation and initial management of neonates at risk for early-onset GBS is reviewed here. Chemoprophylaxis of the mother, established GBS infection in infants and pregnant women, the microbiology and epidemiology of GBS, and the status of GBS vaccines are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-pregnant-women\" class=\"medical medical_review\">&quot;Group B streptococcal infection in pregnant women&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=group-b-streptococcus-virulence-factors-and-pathogenic-mechanisms\" class=\"medical medical_review\">&quot;Group B streptococcus: Virulence factors and pathogenic mechanisms&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">&quot;Vaccines for the prevention of group B streptococcal disease&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">SUMMARY OF MATERNAL IAP GUIDELINES</span></p><p class=\"headingAnchor\" id=\"H6035106\"><span class=\"h2\">Indications for maternal IAP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Indications for maternal intrapartum antibiotic prophylaxis (IAP) are summarized in the table (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. Guidelines for maternal screening and administration of IAP are discussed in detail separately (see <a href=\"#H1597365654\" class=\"local\">'Society guideline links'</a> below and <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>). </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Adequate IAP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For the purposes of infant management, &quot;adequate IAP&quot; is defined as intravenous (IV) penicillin, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, or <a href=\"topic.htm?path=cefazolin-pediatric-drug-information\" class=\"drug drug_pediatric\">cefazolin</a> given &ge;4 hours prior to delivery [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. The four-hour interval is counted from the beginning of the antibiotic infusion because it is easier to determine accurately than the end of the infusion. All other agents (including <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> or <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, which are commonly administered to women with high-risk penicillin allergy) or durations are considered inadequate for prevention of neonatal early-onset GBS disease.</p><p class=\"headingAnchor\" id=\"H2901877\"><span class=\"h1\">MANAGEMENT OF THE NEONATE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Caregivers should have a low threshold for evaluation and treatment of possible early-onset group B streptococcal (GBS) disease because of the potential for serious adverse consequences, including death. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H37\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Outcome'</a>.)</p><p>In the era of universal screening of pregnant women for GBS colonization and use of intrapartum antibiotic prophylaxis (IAP) when warranted, the majority of cases of early-onset GBS among term infants occur in infants born to women who had negative prenatal GBS cultures [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/6-8\" class=\"abstract_t\">6-8</a>].</p><p>Management of the infant whose mother has received GBS chemoprophylaxis is based on the clinical appearance at birth or during the hospital observation period, maternal chorioamnionitis, indications for and adequacy of maternal GBS prophylaxis (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>), gestational age, and duration of rupture of membranes (ROM) (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. Our recommendations are generally consistent with the 2010 Centers for Disease Control and Prevention (CDC) guidelines [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H481658626\"><span class=\"h2\">Risk estimators</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neonatal sepsis risk <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5981\" target=\"_blank\" class=\"external\">calculator</a> is based on multivariate predictive models for risk of bacterial early-onset sepsis (EOS) and has been validated in clinical use referred to as the Neonatal Sepsis Risk Calculator [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/9-12\" class=\"abstract_t\">9-12</a>]. This tool can be used to estimate the risk of EOS in individual patients based on objective data known at the time of birth (eg, highest intrapartum maternal temperature, maternal GBS status, the administration of maternal IAP, gestational age, duration of ROM), combined with the evolving newborn clinical condition in the first 12 hours after birth. The estimated risk of sepsis can be used to help guide decision-making regarding diagnostic evaluation and empiric antibiotic treatment. The thresholds used to trigger evaluation and empiric treatment correspond to a final estimated risk of sepsis of &gt;0.1 percent and &gt;0.3 percent, respectively. These thresholds were validated in a prospective study including &gt;200,000 infants [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/11\" class=\"abstract_t\">11</a>]. Clinicians may use the sepsis risk calculator with different thresholds for evaluation and treatment; however, alternate approaches have not been prospectively validated.</p><p class=\"headingAnchor\" id=\"H2900460\"><span class=\"h2\">Diagnostic evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early-onset GBS disease should be suspected in any infant who is ill-appearing (regardless of maternal GBS colonization status), infants who are born to women with chorioamnionitis (proven or suspected), and infants whose mothers had indications for IAP (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H6035106\" class=\"local\">'Indications for maternal IAP'</a> above and <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H11\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Clinical manifestations'</a>.)</p><p>The indications for and extent of neonatal evaluation depend upon clinical appearance, maternal chorioamnionitis, exposure to maternal IAP, gestational age, and duration of ROM before delivery (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. Risk assessment tools can help guide the decision regarding the extent of evaluation. (See <a href=\"#H481658626\" class=\"local\">'Risk estimators'</a> above.)</p><p class=\"headingAnchor\" id=\"H2908097990\"><span class=\"h3\">Ill-appearing infants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ill-appearance or signs of sepsis (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 2</a>) may be an indication of early-onset GBS, regardless of maternal GBS colonization status [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H8\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Clinical manifestations'</a>.)</p><p>Infants who are ill-appearing or in whom bacterial sepsis is strongly suspected should undergo a full diagnostic evaluation including complete blood count (CBC) with differential and platelet count, blood culture, lumbar puncture, chest radiograph if the infant has respiratory symptoms. Empiric antibiotic therapy should be provided until laboratory results are known (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H2900468\" class=\"local\">'Full evaluation'</a> below and <a href=\"#H2900567\" class=\"local\">'Empiric antibiotic therapy'</a> below.)</p><p>Empiric antibiotic treatment should continue at least until laboratory results are known, typically no longer than 48 hours.</p><p>The subsequent management of ill-appearing infants varies depending upon the clinical syndrome (eg, sepsis, meningitis, pneumonia, etc), pathogen, and clinical course. Management of these syndromes is detailed in separate topic reviews:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neonatal sepsis (see <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H7\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Culture-proven sepsis'</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Meningitis (see <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H7\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Specific therapy'</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pneumonia (see <a href=\"topic.htm?path=neonatal-pneumonia#H24\" class=\"medical medical_review\">&quot;Neonatal pneumonia&quot;, section on 'Treatment'</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>GBS infection (see <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H29\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Definitive therapy'</a>)</p><p/><p class=\"headingAnchor\" id=\"H1510948639\"><span class=\"h3\">Well-appearing infants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For well-appearing infants, the decision to perform a diagnostic evaluation <span class=\"nowrap\">and/or</span> initiate empiric antibiotic therapy is based upon on whether the mother had chorioamnionitis (proven or suspected) or indications for GBS prophylaxis (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>), and if so, whether she received adequate IAP (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>). Risk assessment tools can also help guide decisions regarding evaluation and empiric treatment. (See <a href=\"#H481658626\" class=\"local\">'Risk estimators'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>No maternal indications for IAP</strong> &ndash; Well-appearing infants whose mothers do not have chorioamnionitis (proven or suspected) or indications for GBS prophylaxis (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>) should receive routine newborn care (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. If the infant develops signs of sepsis (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 2</a>) during the birth hospitalization, a full diagnostic evaluation should be conducted and empiric antibiotic therapy initiated. (See <a href=\"topic.htm?path=overview-of-the-routine-management-of-the-healthy-newborn-infant\" class=\"medical medical_review\">&quot;Overview of the routine management of the healthy newborn infant&quot;</a> and <a href=\"#H2908097990\" class=\"local\">'Ill-appearing infants'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maternal chorioamnionitis</strong> &ndash; Well-appearing infants born to women with suspected or proven chorioamnionitis should undergo a limited diagnostic evaluation (including blood culture at birth and CBC with differential and platelet count at birth <span class=\"nowrap\">and/or</span> at 6 to 12 hours of life) and receive empiric antibiotic therapy until laboratory results are known (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H2900551\" class=\"local\">'Limited evaluation'</a> below and <a href=\"#H2900567\" class=\"local\">'Empiric antibiotic therapy'</a> below.)</p><p/><p class=\"bulletIndent1\">If laboratory results are unremarkable and the clinical course is benign, antibiotics should be discontinued after 48 hours of therapy.</p><p/><p class=\"bulletIndent1\">Chorioamnionitis is a risk factor for early-onset GBS disease and may reflect intrauterine onset of infection [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. Consultation with obstetric providers to determine suspicion for chorioamnionitis is an important aspect of neonatal management. Among infants born at &ge;37 weeks gestation, maternal intrapartum fever alone is often used as an obstetric indication to administer intrapartum antibiotics due to suspicion for chorioamnionitis. Intrapartum maternal fever (&ge;100.4 &deg;F) may be considered in combination with other risk factors for early-onset GBS disease to determine neonatal management [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5,9\" class=\"abstract_t\">5,9</a>]. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H9\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Risk factors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mother had indications for IAP AND received adequate IAP</strong> &ndash; For a well-appearing infant (of any gestational age) whose mother had indications for IAP (other than chorioamnionitis) and received adequate IAP (ie, penicillin, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, or <a href=\"topic.htm?path=cefazolin-pediatric-drug-information\" class=\"drug drug_pediatric\">cefazolin</a> at least four hours before delivery), diagnostic testing is not necessary (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\">Most infants in this category should be observed for at least 48 hours. Infants who are &ge;37 weeks gestation can be considered for discharge at &gt;24 hours of age if they otherwise qualify for discharge, can be observed carefully at home, a person able to comply fully with discharge instructions will be present, and the parents have ready access to medical care [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. This recommendation is based upon evidence from retrospective analyses that IAP does not alter the clinical spectrum of disease or the time of onset of clinical signs of infection [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/6,7,13,14\" class=\"abstract_t\">6,7,13,14</a>]. Most infants with early-onset GBS present within the first 24 hours of life. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H12\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Early-onset disease'</a>.)</p><p/><p class=\"bulletIndent1\">If the infant develops signs of sepsis (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 2</a>), a full diagnostic evaluation should be conducted and empiric antibiotic therapy initiated (see <a href=\"#H2908097990\" class=\"local\">'Ill-appearing infants'</a> above).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mother had indications for IAP and received no or inadequate IAP</strong> &ndash; The management of well-appearing infants born to mothers who had an indication for GBS prophylaxis (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>) but did not receive IAP or received inadequate IAP depends upon the gestational age of the infant and the duration of ROM before delivery (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Infants &ge;37 weeks gestation AND ROM &lt;18 hours</strong> &ndash; If the infant is &ge;37 weeks gestational age <strong>and</strong> membranes were ruptured &lt;18 hours before delivery, diagnostic testing is generally not indicated [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. The infant should be observed in the hospital for at least 48 hours. If the infant develops signs of sepsis (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 2</a>), a full diagnostic evaluation should be conducted and empiric antibiotic therapy initiated. (See <a href=\"#H2900468\" class=\"local\">'Full evaluation'</a> below and <a href=\"#H2900567\" class=\"local\">'Empiric antibiotic therapy'</a> below.)</p><p/><p class=\"bulletIndent2\">This approach is supported by the documented low incidence of early-onset sepsis in this group of infants [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Some experts recommend a CBC with differential and platelets at age 6 to 12 hours to evaluate this low-risk group. Laboratory evaluation does not replace the recommendation for observation of these infants in the hospital for at least 48 hours.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Infants &lt;37 weeks gestation OR ROM &ge;18 hours</strong> &ndash; If the infant is well-appearing but &lt;37 weeks gestational age <strong>or</strong> the membranes were ruptured for &ge;18 hours before delivery, the infant should undergo a limited evaluation (including blood culture at birth and CBC with differential and platelet count at birth <span class=\"nowrap\">and/or</span> at 6 to 12 hours of life) and be observed in the hospital for at least 48 hours. (See <a href=\"#H2900551\" class=\"local\">'Limited evaluation'</a> below.)</p><p/><p class=\"bulletIndent2\">If the infants develops signs of sepsis (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 2</a>) or the blood culture is positive, a full diagnostic evaluation should be conducted and empiric antibiotic therapy initiated. (See <a href=\"#H2900468\" class=\"local\">'Full evaluation'</a> below and <a href=\"#H2900567\" class=\"local\">'Empiric antibiotic therapy'</a> below.)</p><p/><p class=\"bulletIndent2\">Our recommendation differs from the 2013 statement from the American Academy of Pediatrics Committee on the Fetus and Newborn suggesting that for well-appearing infants born at &lt;37 weeks gestation whose mothers had indications for IAP but did not receive IAP or received inadequate IAP, the limited evaluation may consist of a CBC with differential and platelet count (blood culture is obtained only if the laboratory studies are abnormal) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/17\" class=\"abstract_t\">17</a>]. We continue to suggest that the limited evaluation include a blood culture for such infants.</p><p/><p class=\"headingAnchor\" id=\"H2900468\"><span class=\"h3\">Full evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The full diagnostic evaluation includes a complete blood count (CBC) with differential and platelet count, a blood culture, a lumbar puncture (unless the infant's clinical status precludes performing the procedure), and a chest radiograph (if the infant has respiratory symptoms) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. The detection of GBS disease is increased by culturing both blood and cerebrospinal fluid [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/18,19\" class=\"abstract_t\">18,19</a>]. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H21\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Evaluation'</a>.)</p><p>The full diagnostic evaluation should be performed in any term or late-preterm newborn who is ill-appearing and in any premature infant in whom sepsis is strongly considered (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>). (See <a href=\"#H2908097990\" class=\"local\">'Ill-appearing infants'</a> above.)</p><p>In addition, a full evaluation may be warranted if there is a high estimated risk of sepsis based on a clinically validated risk <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5981\" target=\"_blank\" class=\"external\">calculator</a>. (See <a href=\"#H481658626\" class=\"local\">'Risk estimators'</a> above.)</p><p class=\"headingAnchor\" id=\"H2900551\"><span class=\"h3\">Limited evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited diagnostic evaluation includes a blood culture at birth and CBC with differential and platelet count at birth <span class=\"nowrap\">and/or</span> at 6 to 12 hours of life [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]. The sensitivity of the CBC as a screen for sepsis improves if the sample is obtained or repeated at 6 to 12 hours of life rather than at birth [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/20-22\" class=\"abstract_t\">20-22</a>]. Exposure to IAP may inhibit the growth of GBS in blood or cerebrospinal fluid cultures, but it does not change the clinical spectrum of disease or the onset of clinical signs of infection within 24 to 48 hours of birth [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/23,24\" class=\"abstract_t\">23,24</a>].</p><p>In accord with the 2010 CDC guidelines, we suggest that limited diagnostic evaluation be performed in (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Well-appearing infants whose mothers have proven or suspected chorioamnionitis (see <a href=\"#H1510948639\" class=\"local\">'Well-appearing infants'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Well-appearing infants whose mothers had indications for intrapartum antibiotic prophylaxis (IAP) (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>) but did not receive IAP or received inadequate IAP <strong>and </strong>(see <a href=\"#H1510948639\" class=\"local\">'Well-appearing infants'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The gestational age is &lt;37 weeks, <strong>or</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Membranes were ruptured for &ge;18 hours</p><p/><p>In addition, a limited evaluation may be warranted if there is a moderately elevated estimated risk of sepsis based on a clinically validated risk <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5981\" target=\"_blank\" class=\"external\">calculator</a>. (See <a href=\"#H481658626\" class=\"local\">'Risk estimators'</a> above.)</p><p>A 2013 statement from the American Academy of Pediatrics Committee on the Fetus and Newborn suggests that for well-appearing infants born at &lt;37 weeks gestation whose mothers had indications for IAP but did not receive IAP or received inadequate IAP, the limited evaluation may consist of a CBC with differential and platelet count (blood culture is obtained only if the laboratory studies are abnormal) [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/17\" class=\"abstract_t\">17</a>]. However, we continue to suggest that the limited evaluation include CBC with differential and platelet count and a blood culture for such infants.</p><p class=\"headingAnchor\" id=\"H2900559\"><span class=\"h3\">Interpretation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical signs are more sensitive than hematologic tests in predicting neonatal sepsis, particularly if the neonate is well-appearing [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/20,25-27\" class=\"abstract_t\">20,25-27</a>].</p><p>Interpretation of the CBC should consider the timing of the evaluation, as well as the gestational age of the infant. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H686757573\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Complete blood count'</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation#H176900390\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;, section on 'Neutrophil counts'</a>.)</p><p class=\"headingAnchor\" id=\"H2900567\"><span class=\"h2\">Empiric antibiotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Indications for empiric antibiotic therapy include (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of neonatal sepsis or ill-appearance (see <a href=\"#H2908097990\" class=\"local\">'Ill-appearing infants'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mother with proven or suspected chorioamnionitis (see <a href=\"#H1510948639\" class=\"local\">'Well-appearing infants'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High estimated sepsis risk based on a clinically validated risk <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5981\" target=\"_blank\" class=\"external\">calculator</a> (see <a href=\"#H481658626\" class=\"local\">'Risk estimators'</a> above)</p><p/><p>The empiric antibiotic regimen should include agents active against GBS (including <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>) and other organisms that cause neonatal sepsis (eg, <em>Escherichia coli</em> and other gram-negative pathogens). The combination of ampicillin and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is generally recommended. However, local antibiotic resistance patterns must be considered. In the era of GBS IAP, up to 40 percent of early-onset sepsis is due to ampicillin-resistant gram-negative organisms [<a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/28,29\" class=\"abstract_t\">28,29</a>]. The addition of a third-generation cephalosporin to the empiric treatment of early-onset sepsis may be warranted, but only among neonates with suspected meningitis. (See <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H4\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Initial empiric therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H1597365654\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Sepsis in neonates&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Group B streptococcal infection in pregnant women and neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=group-b-streptococcal-disease-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Group B streptococcal disease (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines for maternal screening for group B streptococcus (GBS) and administration of intrapartum antibiotic prophylaxis (IAP) are summarized in the table and discussed in detail separately (<a href=\"image.htm?imageKey=PEDS%2F66582\" class=\"graphic graphic_table graphicRef66582 \">table 1</a>). (See <a href=\"#H1597365654\" class=\"local\">'Society guideline links'</a> above and <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The evaluation and empiric antibiotic therapy for early-onset GBS disease in neonates depend upon the newborn's clinical appearance, risk factors for GBS infection (including maternal chorioamnionitis), and adequacy of maternal IAP (if IAP was indicated) (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>). Risk <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5981\" target=\"_blank\" class=\"external\">calculators</a> based on multivariate predictive models can be used to estimate the risk of early-onset sepsis in individual patients which can be used to help guide decision-making regarding the diagnostic evaluation and empiric antibiotic treatment. (See <a href=\"#H2901877\" class=\"local\">'Management of the neonate'</a> above and <a href=\"#H481658626\" class=\"local\">'Risk estimators'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the infant is ill-appearing or sepsis is suspected based on clinical findings or a high estimated sepsis risk based on a clinically validated risk model, a full diagnostic evaluation should be performed. This includes a complete blood count (CBC) with differential and platelet count, a blood culture, and a lumbar puncture (unless the clinical status dictates otherwise), and a chest radiograph if there are respiratory abnormalities. (See <a href=\"#H2908097990\" class=\"local\">'Ill-appearing infants'</a> above and <a href=\"#H2900468\" class=\"local\">'Full evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For well-appearing infants born to women with suspected or proven chorioamnionitis or with a moderately elevated sepsis risk estimate based on a clinically validated risk model, we suggest a limited diagnostic evaluation (blood culture at birth; CBC with differential and platelet count at birth <span class=\"nowrap\">and/or</span> at 6 to 12 hours of life) (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>). (See <a href=\"#H2900551\" class=\"local\">'Limited evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indications for empiric antibiotic therapy include (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) (see <a href=\"#H2900567\" class=\"local\">'Empiric antibiotic therapy'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ill-appearance or signs concerning for neonatal sepsis (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 2</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Mother with proven or suspected chorioamnionitis</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>High estimated sepsis risk based on a clinically validated risk <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5981\" target=\"_blank\" class=\"external\">calculator</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The empiric antibiotic regimen should include agents active against GBS and other organisms that cause neonatal sepsis (eg, <em>Escherichia coli</em> and other gram-negative pathogens). We suggest <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> rather than other agents (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Local antibiotic resistance patterns should be considered. (See <a href=\"#H2900567\" class=\"local\">'Empiric antibiotic therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnostic testing is not necessary for well-appearing infants whose mothers had indications for IAP (other than chorioamnionitis) and received <strong>adequate IAP</strong> (&ge;4 hours of <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a>, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, or <a href=\"topic.htm?path=cefazolin-pediatric-drug-information\" class=\"drug drug_pediatric\">cefazolin</a> before delivery). Most infants in this category should be observed for at least 48 hours. Infants who are &ge;37 weeks gestation can be considered for discharge at &gt;24 hours of age if they otherwise qualify for discharge, can be observed carefully at home, a person able to comply fully with discharge instructions will be present, and the parents have ready access to medical care. (See <a href=\"#H1510948639\" class=\"local\">'Well-appearing infants'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Definitive management of infants with established GBS infection is discussed separately. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H25\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Management'</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/1\" class=\"nounderline abstract_t\">Schuchat A. Group B streptococcus. Lancet 1999; 353:51.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/2\" class=\"nounderline abstract_t\">Schuchat A, Deaver-Robinson K, Plikaytis BD, et al. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. Pediatr Infect Dis J 1994; 13:623.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/3\" class=\"nounderline abstract_t\">Schrag SJ, Farley MM, Petit S, et al. Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to 2014. Pediatrics 2016; 138.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/4\" class=\"nounderline abstract_t\">Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/5\" class=\"nounderline abstract_t\">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/6\" class=\"nounderline abstract_t\">Pulver LS, Hopfenbeck MM, Young PC, et al. Continued early onset group B streptococcal infections in the era of intrapartum prophylaxis. J Perinatol 2009; 29:20.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/7\" class=\"nounderline abstract_t\">Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005; 115:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/8\" class=\"nounderline abstract_t\">Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009; 360:2626.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/9\" class=\"nounderline abstract_t\">Escobar GJ, Puopolo KM, Wi S, et al. Stratification of risk of early-onset sepsis in newborns &ge; 34 weeks' gestation. Pediatrics 2014; 133:30.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/10\" class=\"nounderline abstract_t\">Puopolo KM, Draper D, Wi S, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics 2011; 128:e1155.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/11\" class=\"nounderline abstract_t\">Kuzniewicz MW, Puopolo KM, Fischer A, et al. A Quantitative, Risk-Based Approach to the Management of Neonatal Early-Onset Sepsis. JAMA Pediatr 2017; 171:365.</a></li><li class=\"breakAll\">Kaiser Permanente neonatal early-onset sepsis calculator. Available at: https://neonatalsepsiscalculator.kaiserpermanente.org.</li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/13\" class=\"nounderline abstract_t\">Bromberger P, Lawrence JM, Braun D, et al. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. Pediatrics 2000; 106:244.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/14\" class=\"nounderline abstract_t\">Pinto NM, Soskolne EI, Pearlman MD, Faix RG. Neonatal early-onset group B streptococcal disease in the era of intrapartum chemoprophylaxis: residual problems. J Perinatol 2003; 23:265.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/15\" class=\"nounderline abstract_t\">Hashavya S, Benenson S, Ergaz-Shaltiel Z, et al. The use of blood counts and blood cultures to screen neonates born to partially treated group B Streptococcus-carrier mothers for early-onset sepsis: is it justified? Pediatr Infect Dis J 2011; 30:840.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/16\" class=\"nounderline abstract_t\">Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986; 314:1665.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/17\" class=\"nounderline abstract_t\">Brady MT, Polin RA. Prevention and management of infants with suspected or proven neonatal sepsis. Pediatrics 2013; 132:166.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/18\" class=\"nounderline abstract_t\">Stoll BJ, Hansen N, Fanaroff AA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics 2004; 113:1181.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/19\" class=\"nounderline abstract_t\">Ansong AK, Smith PB, Benjamin DK, et al. Group B streptococcal meningitis: cerebrospinal fluid parameters in the era of intrapartum antibiotic prophylaxis. Early Hum Dev 2009; 85:S5.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/20\" class=\"nounderline abstract_t\">Greenberg DN, Yoder BA. Changes in the differential white blood cell count in screening for group B streptococcal sepsis. Pediatr Infect Dis J 1990; 9:886.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/21\" class=\"nounderline abstract_t\">Christensen RD, Rothstein G, Hill HR, Hall RT. Fatal early onset group B streptococcal sepsis with normal leukocyte counts. Pediatr Infect Dis 1985; 4:242.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/22\" class=\"nounderline abstract_t\">Newman TB, Puopolo KM, Wi S, et al. Interpreting complete blood counts soon after birth in newborns at risk for sepsis. Pediatrics 2010; 126:903.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/23\" class=\"nounderline abstract_t\">Carbonell-Estrany X, Figueras-Aloy J, Salcedo-Abizanda S, et al. Probable early-onset group B streptococcal neonatal sepsis: a serious clinical condition related to intrauterine infection. Arch Dis Child Fetal Neonatal Ed 2008; 93:F85.</a></li><li class=\"breakAll\">Edwards MS, Nizet V, Baker CJ. Group B streptococcal infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2010. p.419.</li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/25\" class=\"nounderline abstract_t\">Ottolini MC, Lundgren K, Mirkinson LJ, et al. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J 2003; 22:430.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/26\" class=\"nounderline abstract_t\">Hsu KK, Pelton SI, Shapiro DS. Detection of group B streptococcal bacteremia in simulated intrapartum antimicrobial prophylaxis. Diagn Microbiol Infect Dis 2003; 45:23.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/27\" class=\"nounderline abstract_t\">Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants &gt;/=2000 grams at birth: A population-based study. Pediatrics 2000; 106:256.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/28\" class=\"nounderline abstract_t\">Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003; 3:201.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis/abstract/29\" class=\"nounderline abstract_t\">Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics 2010; 125:e1031.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5981 Version 22.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">SUMMARY OF MATERNAL IAP GUIDELINES</a><ul><li><a href=\"#H6035106\" id=\"outline-link-H6035106\">Indications for maternal IAP</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Adequate IAP</a></li></ul></li><li><a href=\"#H2901877\" id=\"outline-link-H2901877\">MANAGEMENT OF THE NEONATE</a><ul><li><a href=\"#H481658626\" id=\"outline-link-H481658626\">Risk estimators</a></li><li><a href=\"#H2900460\" id=\"outline-link-H2900460\">Diagnostic evaluation</a><ul><li><a href=\"#H2908097990\" id=\"outline-link-H2908097990\">- Ill-appearing infants</a></li><li><a href=\"#H1510948639\" id=\"outline-link-H1510948639\">- Well-appearing infants</a></li><li><a href=\"#H2900468\" id=\"outline-link-H2900468\">- Full evaluation</a></li><li><a href=\"#H2900551\" id=\"outline-link-H2900551\">- Limited evaluation</a></li><li><a href=\"#H2900559\" id=\"outline-link-H2900559\">- Interpretation</a></li></ul></li><li><a href=\"#H2900567\" id=\"outline-link-H2900567\">Empiric antibiotic therapy</a></li></ul></li><li><a href=\"#H1597365654\" id=\"outline-link-H1597365654\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H2848902\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/5981|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/56780\" class=\"graphic graphic_algorithm\">- Secondary prevention early-onset GBS disease among newborns</a></li></ul></li><li><div id=\"PEDS/5981|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/66582\" class=\"graphic graphic_table\">- Indications for GBS intrapartum antibiotic prophylaxis</a></li><li><a href=\"image.htm?imageKey=PEDS/72985\" class=\"graphic graphic_table\">- Findings neonatal sepsis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Treatment and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants\" class=\"medical medical_review\">Group B streptococcal infection in neonates and young infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-infection-in-pregnant-women\" class=\"medical medical_review\">Group B streptococcal infection in pregnant women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcus-virulence-factors-and-pathogenic-mechanisms\" class=\"medical medical_review\">Group B streptococcus: Virulence factors and pathogenic mechanisms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Management and outcome of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">Neonatal group B streptococcal disease: Prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">Neonatal pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-routine-management-of-the-healthy-newborn-infant\" class=\"medical medical_review\">Overview of the routine management of the healthy newborn infant</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-disease-the-basics\" class=\"medical medical_basics\">Patient education: Group B streptococcal disease (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Group B streptococcal infection in pregnant women and neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Sepsis in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">Vaccines for the prevention of group B streptococcal disease</a></li></ul></div></div>","javascript":null}